MNKD Quote, Financials, Valuation and Earnings

Ovid Therapeutics, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -9210.61%. MannKind Corp.'s return on equity of -- beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

MannKind Corp. has a consensus price target of $9.39, signalling upside risk potential of 67.96%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.19 which suggests that it could grow by 164.95%. Given that Ovid Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Ovid Therapeutics, Inc. is more attractive than MannKind Corp..

MannKind Corp. has a beta of 0.821, which suggesting that the stock is 17.928% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are larger than Ovid Therapeutics, Inc. quarterly revenues of $132K. MannKind Corp.'s net income of $8M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 16.99x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -834.87%. MannKind Corp.'s return on equity of -- beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.

MannKind Corp. has a consensus price target of $9.39, signalling upside risk potential of 67.96%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $90.69 which suggests that it could grow by 5.37%. Given that MannKind Corp. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Protagonist Therapeutics, Inc..

MannKind Corp. has a beta of 0.821, which suggesting that the stock is 17.928% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.221%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are larger than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. MannKind Corp.'s net income of $8M is higher than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Protagonist Therapeutics, Inc.'s PE ratio is 135.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 26.40x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 9.72% compared to MannKind Corp.'s net margin of 42.36%. MannKind Corp.'s return on equity of -- beat United Therapeutics Corp.'s return on equity of 19.2%.

MannKind Corp. has a consensus price target of $9.39, signalling upside risk potential of 67.96%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 7.75%. Given that MannKind Corp. has higher upside potential than United Therapeutics Corp., analysts believe MannKind Corp. is more attractive than United Therapeutics Corp..

MannKind Corp. has a beta of 0.821, which suggesting that the stock is 17.928% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. MannKind Corp.'s net income of $8M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while United Therapeutics Corp.'s PE ratio is 18.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 7.41x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of 34.76%. MannKind Corp.'s return on equity of -- beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

MannKind Corp. has a consensus price target of $9.39, signalling upside risk potential of 67.96%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 4.8%. Given that MannKind Corp. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Vertex Pharmaceuticals, Inc..

MannKind Corp. has a beta of 0.821, which suggesting that the stock is 17.928% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. MannKind Corp.'s net income of $8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 10.23x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.